Adaptimmune Therapeutics Plc (ADAPY)

0.0425 -0.01 (-11.46%) USD  |  OTCM  |  Dec 17, 16:00
More

Adaptimmune Therapeutics Research and Development Expense (Annual): 160.54M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for ADAPY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Biodexa Pharmaceuticals Plc 6.679M
NuCana Plc 23.02M
Autolus Therapeutics Plc 118.79M
Mereo BioPharma Group Plc 20.94M
Bicycle Therapeutics Plc 216.26M